Trevi Therapeutics (Trevi Therapeutics) Float Percentage Of Total Shares Outstanding : 72.59% (As of Apr. 27, 2024)

View and export this data going back to 2019. Start your Free Trial

What is Trevi Therapeutics Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Trevi Therapeutics's float shares is 50.06 Mil. Trevi Therapeutics's total shares outstanding is 68.96 Mil. Trevi Therapeutics's float percentage of total shares outstanding is 72.59%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Trevi Therapeutics's Insider Ownership is 1.53%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Trevi Therapeutics's Institutional Ownership is 12.81%.

Trevi Therapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Trevi Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	50.06	/	68.96
	=	72.59%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Trevi Therapeutics (Trevi Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Trevi Therapeutics Inc (NAS:TRVI) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

195 Church Street, 16th Floor, New Haven, CT, USA, 06510

Website

https://www.trevitherapeutics.com

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.

Executives

Lisa Delfini	officer: Chief Financial Officer	C/O TREVI THERAPEUTICS, INC., 195 CHURCH STREET, FL. 14, NEW HAVEN CT 06510
Farrell Simon	officer: Chief Commercial Officer	C/O TREVI THERAPEUTICS, INC., 195 CHURCH STREET, FLOOR 14, NEW HAVEN CT 06510
David J Clark	officer: Chief Medical Officer	131 HARTWELL AVE, LEXINGTON MA 02421
Tpg Gp A, Llc	10 percent owner	301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102
Scott D Sandell	10 percent owner
Carmen Chang	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
New Enterprise Associates 16, L.p.	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Paul Edward Walker	director	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Forest Baskett	10 percent owner
Peter W. Sonsini	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
Florence Anthony A. Jr.	10 percent owner	5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815
Ali Behbahani	10 percent owner	5425 WISCONSIN AVE, CHEVY CHASE MD 20815
Mohamad Makhzoumi	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
Jon Winkelried	10 percent owner	C/O GOLDMAN, SACHS & CO., 85 BROAD STREET, NEW YORK NY 10004
Christopher Galletta	officer: See Remarks	195 CHURCH STREET, FLOOR 14,, NEW HAVEN CT 06510